0000950170-24-050844.txt : 20240430
0000950170-24-050844.hdr.sgml : 20240430
20240430210210
ACCESSION NUMBER: 0000950170-24-050844
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240429
FILED AS OF DATE: 20240430
DATE AS OF CHANGE: 20240430
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fenton Mary Kay
CENTRAL INDEX KEY: 0001378589
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39856
FILM NUMBER: 24899618
MAIL ADDRESS:
STREET 1: ACHILLION PHARMACEUTICALS
STREET 2: 300 GEORGE STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06511
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cullinan Therapeutics, Inc.
CENTRAL INDEX KEY: 0001789972
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813867811
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-410-4650
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 1350
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, Inc.
DATE OF NAME CHANGE: 20210225
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Management, Inc.
DATE OF NAME CHANGE: 20210107
FORMER COMPANY:
FORMER CONFORMED NAME: Cullinan Oncology, LLC
DATE OF NAME CHANGE: 20191001
4
1
ownership.xml
4
X0508
4
2024-04-29
0001789972
Cullinan Therapeutics, Inc.
CGEM
0001378589
Fenton Mary Kay
C/O CULLINAN THERAPEUTICS, INC.
ONE MAIN STREET, SUITE 1350
CAMBRIDGE
MA
02142
false
true
false
false
Chief Financial Officer
false
Stock Option (Right to Buy)
27.12
2024-04-29
4
A
false
200000
0.00
A
2034-04-29
Common Stock
200000
200000
D
The option represents a right to purchase a total of 200,000 shares of the Issuer's Common Stock, 25% of which will become vested and exercisable on April 29, 2025, with the remaining shares vesting in equal monthly installments over the following three years thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
/s/ Jacquelyn Sumer, Attorney-in-Fact
2024-04-30